| pubmed-article:18210761 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18210761 | lifeskim:mentions | umls-concept:C0008972 | lld:lifeskim |
| pubmed-article:18210761 | lifeskim:mentions | umls-concept:C0205054 | lld:lifeskim |
| pubmed-article:18210761 | lifeskim:mentions | umls-concept:C0494165 | lld:lifeskim |
| pubmed-article:18210761 | lifeskim:mentions | umls-concept:C0694634 | lld:lifeskim |
| pubmed-article:18210761 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:18210761 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:18210761 | lifeskim:mentions | umls-concept:C0205390 | lld:lifeskim |
| pubmed-article:18210761 | lifeskim:mentions | umls-concept:C0796679 | lld:lifeskim |
| pubmed-article:18210761 | lifeskim:mentions | umls-concept:C2826380 | lld:lifeskim |
| pubmed-article:18210761 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:18210761 | pubmed:dateCreated | 2008-1-23 | lld:pubmed |
| pubmed-article:18210761 | pubmed:abstractText | Since November 2005 a clinical trial of intraarterial hepatic chemoembolization (TACE) with irinotecan-eluting beads has been ongoing in 20 patients affected by liver metastases from colorectal cancer in a palliative setting. A high response rate (80%), with reduction of lesional contrast enhancement in all responding patients was found. The procedure was well tolerated by most patients, with a median duration of hospitalization of 3 days (range 1-10 days). The most important adverse event was abdominal pain during the injection. Adequate supportive treatment with antibiotic and antiemetic prophylaxis, dexamethasone, and intravenous hydration is strictly necessary until the serum levels of transaminases are stabilized and in order to prevent infections. Major analgesics such as morphine must be used before and after the procedure. Our results suggest that TACE using irinotecan-eluting beads is feasible and active in pretreated patients with liver metastases from CRC. | lld:pubmed |
| pubmed-article:18210761 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18210761 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18210761 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18210761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18210761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18210761 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18210761 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18210761 | pubmed:issn | 0258-851X | lld:pubmed |
| pubmed-article:18210761 | pubmed:author | pubmed-author:FiorentiniGia... | lld:pubmed |
| pubmed-article:18210761 | pubmed:author | pubmed-author:GiovanisPetro... | lld:pubmed |
| pubmed-article:18210761 | pubmed:author | pubmed-author:RossiSusannaS | lld:pubmed |
| pubmed-article:18210761 | pubmed:author | pubmed-author:AlibertiCamil... | lld:pubmed |
| pubmed-article:18210761 | pubmed:author | pubmed-author:BeneaGiorgioG | lld:pubmed |
| pubmed-article:18210761 | pubmed:author | pubmed-author:TurrisiGinaG | lld:pubmed |
| pubmed-article:18210761 | pubmed:author | pubmed-author:Del... | lld:pubmed |
| pubmed-article:18210761 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18210761 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:18210761 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18210761 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18210761 | pubmed:pagination | 1085-91 | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:meshHeading | pubmed-meshheading:18210761... | lld:pubmed |
| pubmed-article:18210761 | pubmed:articleTitle | Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. | lld:pubmed |
| pubmed-article:18210761 | pubmed:affiliation | Department of Oncology, San Giuseppe Hospital, Azienda Unità Sanitaria Locale 11, Empoli, Florence, Italy. oncologiaempoli@usl11.tos.it | lld:pubmed |
| pubmed-article:18210761 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18210761 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18210761 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18210761 | lld:pubmed |
